Objective:To explore the feasibility and safety of inject tirofiban before percutaneuos coronary intervention in diabetes patients with acute ST-elevation myocardial infarction. Methods:Eighty-six diabetes patients wih acute myocardial infarction with ST segment elevation(STEMI) were randomly divided into tirofiban treatment group (n=41) and conventional treatment group (n=45). The events of cardiovascular diseases (CVD) within one month and six months were studied and compared. Results:There were 9 cases of puncture syndrome in tirofiban treatment group and 9 cases conventional treatment group,and there was no significant difference between two groups. There were 6 events of CVD in tirofiban treatment group and 15 events in conventional treatment group within 1 month(P=0.044),but there were 9 events of CVD in tirofiban treatment group and 19 events in conventional treatment group within 6 months (P=0.045). The recover time of troponinⅠ was (5.5±2.1) day in tirofiban treatment group and (7.9±2.9) day in conventional treatment group(P=0.046). Conclusion:Inject tirofiban before percutaneuos coronary intervention for STEMI with diabates is safety and feasibility,which can reduce events of CVD within one month and six months.